Belgian biotech Galapagos’ (Euronext: GLPG) suffered a disappoint earlier this month, when its already commercialized JAK inhibitor Jyseleca (filgotinib) fell short in the induction cohorts of a Phase III Crohn's disease (CD) trial.
Responding to the development, analytics firm GlobalData noted that the results are expected to shift the attention of the late-stage CD pipeline from established drug classes such as the Janus kinase or the interleukin-23 (IL-23) inhibitors towards developing novel CD therapeutic targets.
Among the 19 assets in late-stage clinical development, only six (ozanimod, etrasimod, obefazimod, TEV-48574, PRA-023, PF-0648065) are being pursued as first-in-class for novel therapeutic targets in CD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze